Insmed Receives FDA Orphan Drug Designation For IPLEX(TM) In The Treatment Of Myotonic Muscular Dystrophy

Insmed Inc. (Nasdaq: INSM), a developer of follow-on biologics and biopharmaceuticals, announced that the Food and Drug Administration (FDA) has granted Orphan Drug Designation for IPLEX(TM) for the treatment of Myotonic Muscular Dystrophy (MMD). Insmed is currently conducting a 24-week Phase III enabling trial for IPLEX(TM) in MMD, and recently was awarded a grant of approximately $2. [click link for full article]

More: continued here

Filed under: Muscular Dystrophy on December 20th, 2007